NOS2 and neoplasm: A preclinical study demonstrated that combining docetaxel with pan-NOS inhibitor NG-monomethyl-l-arginine acetate (L-NMMA) in a xenograft model of MDA-MB-231 decreased Ki67 proliferating cells, enhanced tumor apoptosis, and reduced tumor-initiating capacity of residual tumor cells after chemotherapy to a larger degree than docetaxel alone [29].